Answers are grounded in this paper and cite their sources.
Reliance on commercial Artemia cysts raises hatchery costs and makes hatcheries susceptible to supply fluctuations. The potential of using enriched Moina as an alternative to Artemia for the last stage of Indonesian mahseer ( Tor soro ) larviculture without compromising the production performance was evaluated. Larvae were reared for 28 days and assigned to five terminal-phase replacement windows: 0, 7, 14, 21 or 28 days of enriched Moina feeding, or 0, 25, 50, 75 or 100% of the rearing period (five replicate containers per treatment). Growth, survival, supplied-feed utilization, feed economics, live-feed composition and intestinal morphometry were assessed. Dunnett tests were applied to compare each replacement treatment with the 100% Artemia control. Enriched Moina had a higher crude protein but lower lipid, ash and total measured amino acid concentration than Artemia on a dry matter basis. However, even at 25% substitution, the final weight and feed efficiency were reduced but the survival and three measured intestinal morphometric indices were not significantly different from the control. At ≥ 50% substitution, area and diameter of intestinal folds were reduced and at 75–100% substitution, all measured intestinal indices were reduced. Complete replacement decreased survival from 98.0 to 88.4% and increased the economic conversion ratio by about 6 times. Treatment 25% reduced total feed cost not. Replacing Artemia with enriched Moina only during the last 7 days can therefore reduce Artemia use while maintaining survival and measured intestinal morphology but is not nutritionally or economically equivalent to continuous Artemia feeding.
No takes yet. Share an insight, caveat, or question.
Sunarno et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: